Cipla 将来の成長
Future 基準チェック /16
Cipla利益と収益がそれぞれ年間13.7%と10.4%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に13.1% 13.7%なると予測されています。
主要情報
13.7%
収益成長率
13.71%
EPS成長率
| Pharmaceuticals 収益成長 | 16.6% |
| 収益成長率 | 10.4% |
| 将来の株主資本利益率 | 13.13% |
| アナリストカバレッジ | Good |
| 最終更新日 | 21 May 2026 |
今後の成長に関する最新情報
分析記事 • May 16
Cipla Limited Just Missed EPS By 7.0%: Here's What Analysts Think Will Happen Next
Cipla Limited ( NSE:CIPLA ) missed earnings with its latest annual results, disappointing overly-optimistic...分析記事 • Jan 28
Cipla Limited Just Missed EPS By 48%: Here's What Analysts Think Will Happen Next
The analysts might have been a bit too bullish on Cipla Limited ( NSE:CIPLA ), given that the company fell short of...分析記事 • Nov 02
Analyst Estimates: Here's What Brokers Think Of Cipla Limited (NSE:CIPLA) After Its Second-Quarter Report
Cipla Limited ( NSE:CIPLA ) just released its latest quarterly results and things are looking bullish. Results were...Recent updates
分析記事 • May 16
Cipla Limited Just Missed EPS By 7.0%: Here's What Analysts Think Will Happen Next
Cipla Limited ( NSE:CIPLA ) missed earnings with its latest annual results, disappointing overly-optimistic...
ナラティブの更新 • Apr 27
CIPLA: New CEO, US Respiratory Launch And Biologics Venture Will Steady Outlook
Analysts now place Cipla's fair value at ₹1,429.83, a small move from ₹1,427.58. This reflects refreshed assumptions around revenue growth, profit margin and future P/E expectations.ナラティブの更新 • Apr 12
CIPLA: New CEO And Biologics Venture Will Support Stronger Outlook
Cipla's analyst fair value estimate has been adjusted slightly from about ₹1,436.58 to ₹1,427.58, reflecting updated assumptions around revenue growth, profit margins and future P/E expectations according to analysts. What's in the News Cipla plans a board meeting on May 13, 2026, to review standalone and consolidated audited financial results for the quarter and year ended March 31, 2026, and to consider a final dividend for the year, if any (company filing).ナラティブの更新 • Mar 27
CIPLA: New CEO And Biologics Venture Will Support Stronger Long Term Outlook
Analysts have trimmed Cipla's implied fair value price target slightly from ₹1,446.31 to ₹1,436.58, reflecting updated views on its revenue growth, profit margin outlook, and future P/E assumptions. What's in the News A board meeting is scheduled for 19 Mar 2026 to consider appointing P R Ramesh, Lead Independent Director, as Vice Chairman, and to take up the planned exit of Independent Director Robert Stewart after completion of his current term, along with other matters (Key Developments).ナラティブの更新 • Mar 13
CIPLA: Pfizer Alliance And CEO Transition Will Shape Steady Forward Outlook
Analysts have kept their Cipla price target unchanged at ₹1,446.31, reflecting consistent assumptions on discount rate, revenue growth, profit margin and future P/E in their models. What's in the News Cipla has agreed to a 60:40 joint venture with Kemwell Biopharma in India to develop, obtain licenses for, manufacture, commercialise, import and export biologic products, with scope to license or outsource these activities (company announcement).ナラティブの更新 • Feb 27
CIPLA: Pfizer Tie-Up And Leadership Shift Will Shape Balanced Outlook
Analysts have trimmed their price target on Cipla by about ₹10 to reflect slightly softer assumptions around long term revenue growth and profit margins, while keeping the P/E framework broadly unchanged. What's in the News Pfizer India and Cipla entered into a partnership under which Cipla will exclusively market and distribute four Pfizer brands in India, including Corex Dx, Corex LS, Dolonex, Neksium and Dalacin C, while Pfizer continues to manufacture and supply these medicines (Key Developments).ナラティブの更新 • Feb 13
CIPLA: Pfizer Partnership And Upcoming Results Will Guide Balanced Future Expectations
Analysts have trimmed their price target for Cipla slightly to ₹1,456 from about ₹1,459, reflecting updated assumptions on discount rate, revenue growth, profit margin and future P/E that are broadly in line with prior views. What's in the News Pfizer India and Cipla entered into a partnership under which Cipla will exclusively market and distribute four Pfizer brands in India, covering Corex Dx and Corex LS cough syrups, Dolonex (NSAID), Neksium (PPI) and Dalacin C (oral antibiotic).ナラティブの更新 • Jan 30
CIPLA: Pfizer Alliance And Upcoming Results Will Shape Measured Future Upside Potential
Analysts have revised their fair value estimate for Cipla to ₹1,458.53, down from ₹1,657.58, citing updated assumptions for revenue growth, profit margins and future P/E multiples. What's in the News Cipla has scheduled a board meeting on Jan 23, 2026, at 11:00 Indian Standard Time to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (company filing).分析記事 • Jan 28
Cipla Limited Just Missed EPS By 48%: Here's What Analysts Think Will Happen Next
The analysts might have been a bit too bullish on Cipla Limited ( NSE:CIPLA ), given that the company fell short of...分析記事 • Jan 17
The Market Doesn't Like What It Sees From Cipla Limited's (NSE:CIPLA) Earnings Yet
With a price-to-earnings (or "P/E") ratio of 20.7x Cipla Limited ( NSE:CIPLA ) may be sending bullish signals at the...ナラティブの更新 • Jan 16
CIPLA: Pfizer Partnership And Leadership Transition Will Support Future Upside Potential
Analysts have slightly reduced their fair value estimate for Cipla to ₹1,658 from ₹1,677, citing updated assumptions that combine modestly higher revenue growth expectations with some pressure on profit margins and a marginally adjusted future P/E multiple. What's in the News A board meeting is scheduled on January 23, 2026, to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).分析記事 • Dec 29
We Think Cipla (NSE:CIPLA) Can Stay On Top Of Its Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Nov 20
Does Cipla (NSE:CIPLA) Deserve A Spot On Your Watchlist?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...分析記事 • Nov 02
Analyst Estimates: Here's What Brokers Think Of Cipla Limited (NSE:CIPLA) After Its Second-Quarter Report
Cipla Limited ( NSE:CIPLA ) just released its latest quarterly results and things are looking bullish. Results were...分析記事 • Sep 24
Cipla Limited's (NSE:CIPLA) Prospects Need A Boost To Lift Shares
With a price-to-earnings (or "P/E") ratio of 22.9x Cipla Limited ( NSE:CIPLA ) may be sending bullish signals at the...分析記事 • Sep 06
Cipla (NSE:CIPLA) Seems To Use Debt Quite Sensibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...ナラティブの更新 • Sep 04
Emerging Markets And Chronic Therapies Will Open New Horizons
With consensus forecasts for both revenue growth (8.4% p.a.) and net profit margin (15.92%) remaining steady, Cipla's Analyst Price Target was left unchanged at ₹1677. What's in the News Cipla is significantly expanding its US manufacturing capacity with an 83,000-square-foot addition at its Fall River, Massachusetts facility, focusing on complex respiratory products, and will utilize advanced technology to enhance production and efficiency.分析記事 • Jul 13
Here's Why Cipla (NSE:CIPLA) Has Caught The Eye Of Investors
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...分析記事 • Jun 03
Here's Why Cipla (NSE:CIPLA) Can Manage Its Debt Responsibly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
新しいナラティブ • Nov 10
Aspirational Inhalation Launches And African Expansion Propel Growth Ambitions
Planned respiratory therapies and product launches could drive increased revenue and enhance the chronic therapy segment's growth.業績と収益の成長予測
| 日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
|---|---|---|---|---|---|
| 3/31/2029 | 378,943 | 57,759 | 37,701 | 55,901 | 14 |
| 3/31/2028 | 346,374 | 51,196 | 36,108 | 49,851 | 35 |
| 3/31/2027 | 310,811 | 41,864 | 30,077 | 43,810 | 35 |
| 3/31/2026 | 277,117 | 38,792 | 9,048 | 39,400 | N/A |
| 12/31/2025 | 279,672 | 45,464 | N/A | N/A | N/A |
| 9/30/2025 | 279,658 | 54,411 | 27,544 | 42,949 | N/A |
| 6/30/2025 | 274,796 | 53,925 | N/A | N/A | N/A |
| 3/31/2025 | 272,674 | 52,725 | 34,653 | 50,050 | N/A |
| 12/31/2024 | 267,201 | 49,897 | N/A | N/A | N/A |
| 9/30/2024 | 262,642 | 44,751 | 29,520 | 45,008 | N/A |
| 6/30/2024 | 258,922 | 43,035 | N/A | N/A | N/A |
| 3/31/2024 | 255,367 | 41,216 | 27,846 | 41,339 | N/A |
| 12/31/2023 | 251,163 | 37,082 | N/A | N/A | N/A |
| 9/30/2023 | 243,407 | 34,532 | 25,988 | 37,924 | N/A |
| 6/30/2023 | 235,108 | 31,112 | N/A | N/A | N/A |
| 3/31/2023 | 225,593 | 28,019 | 20,736 | 32,377 | N/A |
| 12/31/2022 | 222,187 | 26,383 | N/A | N/A | N/A |
| 9/30/2022 | 218,874 | 25,660 | 20,120 | 29,160 | N/A |
| 6/30/2022 | 216,105 | 24,884 | N/A | N/A | N/A |
| 3/31/2022 | 217,078 | 25,168 | 26,285 | 33,259 | N/A |
| 12/31/2021 | 210,718 | 25,681 | N/A | N/A | N/A |
| 9/30/2021 | 207,616 | 25,876 | 28,362 | 37,113 | N/A |
| 6/30/2021 | 202,801 | 25,417 | N/A | N/A | N/A |
| 3/31/2021 | 191,205 | 24,049 | 29,418 | 37,552 | N/A |
| 12/31/2020 | 188,779 | 22,374 | N/A | N/A | N/A |
| 9/30/2020 | 180,802 | 18,403 | 23,627 | 31,968 | N/A |
| 6/30/2020 | 174,377 | 16,462 | N/A | N/A | N/A |
| 3/31/2020 | 170,805 | 15,465 | 20,684 | 30,685 | N/A |
| 12/31/2019 | 171,206 | 16,678 | N/A | N/A | N/A |
| 9/30/2019 | 167,572 | 16,489 | N/A | 25,720 | N/A |
| 6/30/2019 | 163,733 | 15,546 | N/A | N/A | N/A |
| 3/31/2019 | 163,232 | 15,277 | N/A | 16,911 | N/A |
| 12/31/2018 | 155,224 | 13,391 | N/A | N/A | N/A |
| 9/30/2018 | 154,287 | 14,074 | N/A | N/A | N/A |
| 6/30/2018 | 154,992 | 14,530 | N/A | N/A | N/A |
| 3/31/2018 | 151,053 | 14,105 | N/A | 14,628 | N/A |
| 12/31/2017 | 147,618 | 11,701 | N/A | N/A | N/A |
| 9/30/2017 | 144,951 | 11,444 | N/A | N/A | N/A |
| 6/30/2017 | 141,637 | 10,762 | N/A | N/A | N/A |
| 3/31/2017 | 143,340 | 10,064 | N/A | 23,818 | N/A |
| 12/31/2016 | 142,509 | 11,213 | N/A | N/A | N/A |
| 9/30/2016 | 137,547 | 10,071 | N/A | N/A | N/A |
| 6/30/2016 | 134,335 | 12,219 | N/A | N/A | N/A |
| 3/31/2016 | 135,480 | 13,600 | N/A | 17,408 | N/A |
| 12/31/2015 | 135,044 | 16,847 | N/A | N/A | N/A |
| 9/30/2015 | 131,633 | 16,694 | N/A | N/A | N/A |
| 6/30/2015 | 124,782 | 15,368 | N/A | N/A | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: CIPLAの予測収益成長率 (年間13.7% ) は 貯蓄率 ( 6.9% ) を上回っています。
収益対市場: CIPLAの収益 ( 13.7% ) Indian市場 ( 16.3% ) よりも低い成長が予測されています。
高成長収益: CIPLAの収益は増加すると予測されていますが、大幅には増加しません。
収益対市場: CIPLAの収益 ( 10.4% ) Indian市場 ( 10.8% ) よりも低い成長が予測されています。
高い収益成長: CIPLAの収益 ( 10.4% ) 20%よりも低い成長が予測されています。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: CIPLAの 自己資本利益率 は、3年後には低くなると予測されています ( 13.1 %)。
成長企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/22 07:18 |
| 終値 | 2026/05/22 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2026/03/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Cipla Limited 35 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。56
| アナリスト | 機関 |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Gaurav Tinani | Ambit Capital |
| null null | Anand Rathi Shares and Stock Brokers Limited |